OTLC — Oncotelic Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $23.97m
- $36.19m
Annual income statement for Oncotelic Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.74 | 0 | 0 | 0.07 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 9.67 | 8.81 | 9.98 | 7.09 | 3.66 |
| Operating Profit | -7.93 | -8.81 | -9.98 | -7.02 | -3.66 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.97 | -10.5 | 4.68 | -8.21 | -4.78 |
| Net Income After Taxes | -9.97 | -10.5 | 4.68 | -8.21 | -4.78 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.5 | -9.39 | 5.09 | -7.9 | -4.52 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.5 | -9.39 | 5.09 | -7.9 | -4.52 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.104 | -0.032 | 0.021 | -0.004 | -0.003 |